Check out your Company Bowl for anonymous work chats.
Check out Precigen's new UltraCAR-T video providing an overview of our multigenic autologous CAR-T platform with an overnight manufacturing process using our proprietary UltraPorator electroporation system.
Precigen has been shortlisted as an Innovation Award finalist for this year's ScripAwards for our UltraPorator 24-hour system for decentralized CAR-T manufacturing.
Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™
Check out this article in BioProcess Online discussing how Precigen is among the only companies practicing decentralized cell therapy in the field.
Precigen: ‘Electroporation a game changer for cell therapy production’
Read the newly published preclinical evaluation of Precigen’s PRGN-2009, a therapeutic gorilla adenovirus HPV vaccine, and its promising preclinical anti-tumor efficacy and induction of HPV-specific T cells.
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
Precigen announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I clinical trial of Precigen's PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP).
Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition
Exciting news at Precigen! First patients dosed with UltraPorator manufactured PRGN-3005 UltraCAR-T cells at University of Washington/Fred Hutchinson Cancer Research Center and PRGN-3006 UltraCAR-T cells at Moffitt Cancer Center.
